The manufacturing of medicinal products is for us not only a matter of implementing a certain technological process, but a human mission based on high standards of quality, safety and efficacy of medications
SOPHARMA AD (the “Company”) hereby informs that from 20 February 2014 up to and including 26 February 2014 the Company sold 10 111 own shares representing 0.0077% of the share capital of the Company, to the total value of 44 764.85 BGN on the Bulgarian Stock Exchange, the average price per share was 4.43 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 019 262, representing 3.80% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for February 2014 the Company realized a decrease of sales revenues of 1% compared to the same period of 2013, including 20% increase of domestic sales and 6% decrease of export sales.
During the past two months Sopharma AD recorded an increase of sales revenues of 2%, including 11% increase of domestic sales and 1% decrease of export sales compared to 2013.
SOPHARMA AD (the “Company”) hereby informs that from 6 March 2014 up to and including 12 March 2014 the Company bought 818 own shares representing 0.0006% of the share capital of the Company, to the total value of 3 692.65 BGN on the Bulgarian Stock Exchange, the average price per share was 4.51 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 020 080, representing 3.80% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 13 March 2014 up to and including 19 March 2014 the Company bought 12 999 own shares representing 0.01% of the share capital of the Company, to the total value of 58 147.58 BGN on the Bulgarian Stock Exchange, the average price per share was 4.47 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 033 079, representing 3.81% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 20 March 2014 up to and including 26 March 2014 the Company sold 8 894 own shares representing 0.007% of the share capital of the Company, to the total value of 40 702.95 BGN on the Bulgarian Stock Exchange, the average price per share was 4.58 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 5 024 185, representing 3.81% of the share capital of the Company.
SOPHARMA AD (the “Company”) notifies that for March 2014 the Company realized an increase of sales revenues of 16% compared to the same period of 2013, including 10% decrease of domestic sales and 32% increase of export sales.
During the past three months Sopharma AD recorded an increase of sales revenues of 6%, including 3% increase of domestic sales and 8% increase of export sales compared to 2013.
SOPHARMA AD (the “Company”) hereby informs that from 3 April 2014 up to and including 9 April 2014 the Company bought 26 925 own shares representing 0.02% of the share capital of the Company, to the total value of 119 498.00 BGN on the Bulgarian Stock Exchange, the average price per share was 4.44 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 982 810, representing 3.77% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 10 April 2014 up to and including 16 April 2014 the Company bought 4 125 own shares representing 0.003% of the share capital of the Company, to the total value of 18 136.84 BGN on the Bulgarian Stock Exchange, the average price per share was 4.40 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 986 935, representing 3.78% of the share capital of the Company.
SOPHARMA AD (the “Company”) hereby informs that from 17 April 2014 up to and including 23 April 2014 the Company bought 1 500 own shares representing 0.0011% of the share capital of the Company, to the total value of 6 575 BGN on the Bulgarian Stock Exchange, the average price per share was 4.38 BGN.
The trading of treasury shares is pursuant to decision by the Annual General Meeting of Shareholders from 23 June 2010.
The total number of treasury shares after these transactions is 4 988 435, representing 3.78% of the share capital of the Company.
Sopharma AD (the “Company”) notifies that for April 2014 the Company realized a decrease of sales revenues of 9% compared to the same period of 2013, including 1% increase of domestic sales and 12% decrease of export sales.
During the past four months Sopharma AD recorded an increase of sales revenues of 2%, including 2% increase of domestic sales and 2% increase of export sales compared to 2013.